The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease  by DeMeo, Dawn L. et al.
www.ajhg.org DeMeo et al.: SERPINE2 and COPD 253
The SERPINE2 Gene Is Associated with Chronic Obstructive
Pulmonary Disease
Dawn L. DeMeo,1,2,4 Thomas J. Mariani,2,4 Christoph Lange,5 Sorachai Srisuma,2,4,10
Augusto A. Litonjua,1,3,4 Juan C. Celedo´n,1,3,4 Stephen L. Lake,1,4 John J. Reilly,2,4
Harold A. Chapman,11 Brigham H. Mecham,2,4 Kathleen J. Haley,2,4 Jody S. Sylvia,1
David Sparrow,1,2,4,6,7 Avrum E. Spira,7,8 Jennifer Beane,8 Victor Pinto-Plata,9
Frank E. Speizer,1,4,5 Steven D. Shapiro,2,4 Scott T. Weiss,1,4,5 and Edwin K. Silverman1,2,4
1Channing Laboratory and 2Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital,
3Division of Pulmonary and Critical Care Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, 4Harvard Medical
School, 5Harvard School of Public Health, 6Veterans Affairs Medical Center, 7The Pulmonary Center and 8Bioinformatics Program, College of
Engineering, Boston University Medical Center, and 9Division of Pulmonary and Critical Care, Department of Medicine, Caritas-St. Elizabeth’s
Medical Center, Boston; 10Department of Physiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok; and 11Division of
Pulmonary and Critical Care Medicine, Department of Medicine, University of California at San Francisco, San Francisco
Chronic obstructive pulmonary disease (COPD) is a complex human disease likely inﬂuenced by multiple genes,
cigarette smoking, and gene-by-smoking interactions, but only severe alpha 1-antitrypsin deﬁciency is a proven
genetic risk factor for COPD. Prior linkage analyses in the Boston Early-Onset COPD Study have demonstrated
signiﬁcant linkage to a key intermediate phenotype of COPD on chromosome 2q. We integrated results from murine
lung development and human COPD gene–expression microarray studies with human COPD linkage results on
chromosome 2q to prioritize candidate-gene selection, thus identifying SERPINE2 as a positional candidate sus-
ceptibility gene for COPD. Immunohistochemistry demonstrated expression of serpine2 protein inmouse and human
adult lung tissue. In family-based association testing of 127 severe, early-onset COPD pedigrees from the Boston
Early-Onset COPD Study, we observed signiﬁcant association with COPD phenotypes and 18 single-nucleotide
polymorphisms (SNPs) in the SERPINE2 gene. Association of ﬁve of these SNPs with COPD was replicated in a
case-control analysis, with cases from the National Emphysema Treatment Trial and controls from the Normative
Aging Study. Family-based and case-control haplotype analyses supported similar regions of association within the
SERPINE2 gene. When signiﬁcantly associated SNPs in these haplotypic regions were included as covariates in
linkage models, LOD score attenuation was observed most markedly in a smokers-only linkage model (LOD 4.41,
attenuated to 1.74). After the integration of murine and human microarray data to inform candidate-gene selection,
we observed signiﬁcant family-based association and independent replication of association in a case-control study,
suggesting that SERPINE2 is a COPD-susceptibility gene and is likely inﬂuenced by gene-by-smoking interaction.
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Chronic obstructive pulmonary disease (COPD [MIM
606963]) is a complex human disease likely inﬂuenced
by multiple genes, environmental factors (especially cig-
arette smoking), and gene-by-smoking interactions. As
the worldwide disease burden of COPD continues to in-
crease, better treatments may be developed through un-
derstanding the variable susceptibility for developing
this devastating lung disease. Cigarette smoking is the
most important environmental risk factor for the de-
velopment of COPD, but individuals vary widely in their
susceptibility to the pulmonary effects of tobacco smoke
(Burrows et al. 1977).
The only proven genetic risk factor for COPD is severe
deﬁciency of alpha 1-antitrypsin (Laurell and Eriksson
1963). However, this genetic deﬁciency is present in only
1% of individuals with COPD, suggesting that COPD
represents a complex disease with contributions from
multiple genes and environmental risk factors. Genome-
wide linkage analyses in the Boston Early-Onset COPD
Study have helped to narrow the scope of candidate-
gene investigation for COPD (Silverman et al. 2002a,
2002b; Palmer et al. 2003), but the linkage peaks deﬁned
still represent large genomic regions with many biolog-
ically plausible candidate genes. Candidate-gene asso-
ciation studies based on the known pathophysiology of
COPD have been characterized by inconsistent replica-
tion of positive association results (Hersh et al. 2005).
Signiﬁcant linkage of an intermediate phenotype of
COPD—the ratio of forced expiratory volume at one
second to forced vital capacity (FEV1/FVC)—with chro-
mosome 2q has been observed in extended pedigrees
ascertained through probands with severe, early-onset
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Figure 1 Gene expression during normal murine lung development. We assessed the expression of genes within the chromosome 2–linked
locus, using a microarray data set of normal mouse lung development. Shown are the expression proﬁles for 25 probe sets, representing 23
mouse orthologues for human genes present within the locus. Signal intensities were determined using MAS 4.0. Most genes were expressed
at low levels in the lung (signal intensity !4,000); seven genes were expressed at a signal intensity 14,000. Three of these genes were expressed
at a signal intensity 115,000 during at least one time point, including RPL37A (a ribosomal protein), ITM2C (an integral membrane protein
highly expressed in brain), and SERPINE2. E p embryonic day; P p postnatal day; AD p adult.
COPD in the Boston Early-Onset COPD Study (Silver-
man et al. 2002b; Palmer et al. 2003). This region of
linkage likely harbors genes that contribute to COPD
susceptibility through gene-by-smoking interactions (De-
Meo et al. 2004). A similar region on chromosome 2q
has been linked to FEV1/FVC in the general population
(Malhotra et al. 2003).
We intersected human linkage results on chromosome
2q with data from expression-array analysis of murine
and human lung tissues, to prioritize the investigation
of positional COPD candidate genes in this region and
to identify new candidate genes for COPD. Using this
methodology, we identiﬁed SERPINE2 for further inves-
tigation as a novel candidate COPD-susceptibility gene,
potentially relevant in both early-onset and later-onset
COPD not related to alpha 1-antitrypsin deﬁciency.
Methods
Murine Expression-Array Experiments
We evaluated the expression of genes within a genomic re-
gion on chromosome 2q bracketed by positions 212,742,577
and 230,264,438 (UCSC Genome Bioinformatics); this region
represents the 1.5-LOD unit of support interval for linkage on
2q (Silverman et al. 2002b). We evaluated the expression of
genes within this genomic region in a microarray data set of
normal mouse lung development, generated using the Affymet-
rix Mu11K platform (Mariani et al. 2002). Sequence veriﬁ-
cation of microarray probe sets was performed using the Ref-
erence Sequence database with the resources available at the
Lung TranscriptomeWeb site, as described elsewhere (Mecham
et al. 2004). Tests for signiﬁcance of fold change were per-
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Figure 2 SERPINE2 localization in normal adult mouse lung. Immunohistochemistry for SERPINE2 in the normal adult mouse lung
was performed using a rabbit polyclonal antibody (PN1). Staining was evident in small airway (AW)–conducting epithelium (EPI) and in the
vascular (V) adventitia in an extracellular matrix-associated (ECM) pattern. No staining was observed for control IgG.
formed using the variable fold-change threshold method (Mar-
iani et al. 2003).
Human COPD Microarray Experiments
A human microarray data set was available, generated using
the Affymetrix human U133A platform; a complete description
of case and control selection has been published elsewhere
(Spira et al. 2004). This data set included 34 lung tissue sam-
ples; 18 were from individuals withmoderate-to-severe emphy-
sema who underwent lung volume–reduction surgery (LVRS)
for COPD, and 16 were non-LVRS normal-to-minimally em-
physematous control human lung samples from individuals
undergoing pulmonary nodule resection. Expression valueswere
generated from the raw image ﬁles by use of the robust micro-
array averaging method (Irizarry et al. 2003), including the
quantile normalization procedure, as implemented in Biocon-
ductor. Pulmonary function test information was available
for these patients, including pre- and postbronchodilator FEV1,
FEV1/FVC, total lung capacity (TLC), diffusing capacity for
carbon monoxide (DLCO), and intensity of smoking (pack-
years [number of packs smoked per day multiplied by the
number of smoking years] of cigarettes smoked). The sig-
niﬁcance analysis of microarray (SAM) method (Tusher et al.
2001) was implemented using the publicly available TIGR
Multi-Array Viewer (MEV) software (TM4). Additionally, the
Pearson and Spearman rank correlations were calculated for
the association of SERPINE2 expression with each of the lung
function parameters. The signiﬁcance of each correlation was
determined using the Student’s t test. Raw data from the hu-
man microarray experiments have been deposited in the Na-
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Figure 3 SERPINE2 localization in human lung. SERPINE2 immunostaining was observed in normal (A), emphysematous (C), and
asthmatic (D) human lung. Staining was evident in small airway epithelial cells (EPI) and in the vascular adventitia extracellular matrix (ECM).
No staining was observed for control IgG (B).
tional Center for Biotechnology Information (NCBI) Gene Ex-
pression Omnibus (series reference number GSE1650).
Immunohistochemistry
Immunostaining in normal adult mouse and human lung
tissue was performed using a rabbit polyclonal antibody raised
against recombinant bovine serpine2. The polyclonal antibod-
ies were produced in rabbits against bovine serpine2, by use
of recombinant, puriﬁed serpine2 and bovine follicular ﬂuid.
The antibodies were validated by immunoblotting. The anti-
bodies used in our mouse and human immunohistochemistry
experiments were a generous gift from Dr. J. G. Lussier. The
complete method of the serpine2 antibody development has
been described elsewhere (Bedard et al. 2003).
Human Populations for Genetic Association Studies
Three separate cohorts were analyzed, including partici-
pants in the Boston Early-Onset COPD Study, the National
Emphysema Treatment Trial (NETT), and the Normative Ag-
ing Study (NAS). The Partners Institutional Review Board (IRB)
for human studies approved the study protocols. Anonymized
data sets were used for the NAS participants, as approved by
the IRBs of both Partners and the Veterans Administration
Hospitals.
Boston Early-Onset COPD Study
The recruitment and characteristics of probands and family
members enrolled in the Boston Early-Onset COPD Study have
been reported elsewhere (Silverman et al. 1998). In brief, as-
certainment criteria for probands in the Boston Early-Onset
COPD Study included an FEV1 !40% of predicted, age !53
years, and no evidence of severe alpha 1-antitrypsin deﬁciency.
All available ﬁrst-degree and older second-degree relatives were
invited to participate in the study; there were 127 probands
and a total of 949 individuals in the family-based association
analysis for SERPINE2.
Each study participant completed a modiﬁed version of the
1978 American Thoracic Society–Division of Lung Diseases
respiratory questionnaire (Ferris 1978). Spirometry was per-
formed as described elsewhere (Silverman et al. 1998). Most
individuals completed pre- and postbronchodilator spirometry
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Table 1
SERPINE2 SNPs Genotyped and Analyzed in the Family-Based and Case-Control Association
Analyses
SNP ID SNP Alleles Position
Location from
ATG Start Site
1 rs282253 C/G 5′ Genomic/promoter g.39863
2 rs1438831 C/T 5′ Genomic/promoter g.39698
3 rs7579646 A/G Intron 1 g.34079
4 rs840088 C/T Intron 1 g.33227
5 rs7562213 A/G Intron 1 g.31810
6 rs920251 A/G Intron 1 g.26328
7 rs1371029 A/G Intron 1 g.21856
8 rs2099601 A/C Intron 1 g.18689
9 rs2083120 C/T Intron 1 g.18591
10 rs2083121 C/T Intron 1 g.18385
11 rs2099602 C/T Intron 1 g.18298
12 rs4674849 C/T Intron 1 g.18228
13 rs4574111 A/G Intron 1 g.17755
14 rs1438829 C/T Intron 1 g.17086
15 rs6436459 C/T Intron 1 g.14397
16 rs1371028 C/T Intron 1 g.12833
17 rs1438828 A/G Intron 1 g.11684
18 rs1866152 C/T Intron 1 g.11462
19 rs7588220 A/G Intron 1 g.6987
20 rs1530020 G/T Intron 1 g.4753
21 rs1530021 C/T Intron 1 g.4619
22 rs6436454 C/T Intron 1 g.4104
23 rs3948261 A/G Intron 1 g.3275
24 rs2118409 C/G Intron 1 g.3026
25 rs6742903 C/T Intron 1 g.2176
26 rs12436 A/C Exon 2 g.41
27 ss49785623 A/G Exon 2 g.190
28 rs7581619 A/G Exon 2 g.230
29 rs3795877 C/T Intron 2 g.440
30 rs1866153 A/G Intron 2 g.2065
31 rs6747096 A/G Exon 3 g.3775
32 rs3795879 C/T Intron 3 exon/intron boundary g.3796
33 ss49785624 A/C Intron 3 g.3917
34 rs6715768 A/G Intron 3 g.4126
35 rs6738983 C/T Intron 3 g.7867
36 rs6721140 A/G Intron 3 g.7974
37 rs2076924 C/T Intron 3 g.9573
38 rs6712954 A/G Exon 4 g.9967
39 rs2099603 A/G Intron 4 g.13936
40 rs7605945 C/T Intron 5 g.18811
41 rs975278 C/T Intron 5 g.18910
42 rs10164837 C/T Intron 6 g.19349
43 rs729631 C/G Intron 7 g.21698
44 ss49785625 A/G Intron 7 g.21753
45 rs7597833 C/T Intron 8 g.24467
46 ss49785626 C/T Intron 8 g.24583
47 rs6734100 C/G Intron 8 g.24622
48 rs1025734 C/T 3′ Genomic g.31248
NOTE.—Position in Human Genome Working Draft (Goldenpath hg17, dbSNP123) fromUCSC
Genome Bioinformatics.
(performed ∼15 minutes after albuterol administration); we
focused on the results from postbronchodilator trials (Palmer
et al. 2003). For the analysis of quantitative phenotypes, ab-
solute volume spirometric results with covariate adjustment,
as detailed below, were used in all analyses. For the analysis
of qualitative phenotypes, percent predicted values for FEV1
and FEV1/FVC were calculated for white adult participants by
use of equations formulated by Crapo et al. (1981). For white
individuals aged !18 years, predicted values were determined
from equations by Hsu et al. (1979), with predicted values for
FEV1/FVC calculated from equations by Knudson et al. (1983).
For African American participants, predicted values were de-
258 The American Journal of Human Genetics Volume 78 February 2006 www.ajhg.org
Table 2
PBAT of Quantitative Spirometric Phenotypes with SERPINE2 SNPs, Including a
SNP-by-Smoking Interaction Term
SNP ALLELE
P BY SPIROMETRIC TEST
FEV1
Postbronchodilator
FEV1/FVC
Postbronchodilator
rs7579646 G .0009 .0008
rs6436459 C .009 .0005
rs1530020 A .02 .05
rs6436454 T .01 .02
rs3948261 T .02 .05
rs2118409 C .04 NS
rs3795877 A .009 .002
rs6747096 A .02 .001
rs3795879 C NS .007
rs6715768 G .0004 .0007
rs7605945 C .004 .0004
rs975278 T NS .00006
rs729631 C NS .001
ss49785625 A .004 NS
rs7597833 T .007 NS
rs6734100 G .01 .00004
NOTE.—Exact P values are presented unless ; each model was analyzedP 1 .05
under the assumption of an additive mode of inheritance and adjusted for age, age2,
height, height2, pack-years, pack-years2, sex, and a SNP–by–pack-years interaction
term. NS p not signiﬁcant.
Table 3
PBAT of Qualitative Spirometric Phenotypes with SERPINE2 SNPs,
Including a SNP-by-Smoking Interaction Term
SNP ALLELE
P BY COPD SEVERITY
Moderate to Severe Mild to Severe
rs840088 C .0004 NS
rs6436459 C .0003 .002
rs1530020 A .02 .01
rs975278 T .03 NS
ss49785625 A .02 .01
rs7597833 T .03 .007
rs6734100 G .003 NS
rs1025734 T NS .03
NOTE.—Exact P values are presented unless ; each modelP 1 .05
was analyzed under the assumption of an additive mode of inheritance
and adjusted for age, age2, height, height2, pack-years, pack-years2,
sex, and a SNP–by–pack-years interaction term.
termined by equations developed by Hankinson et al. (1999).
For the qualitative analysis, an FEV1 !60% predicted in the
presence of FEV1/FVC !90% predicted deﬁned moderate-to-
severe COPD; FEV1 !80% predicted in the presence of FEV1/
FVC !90% predicted deﬁned mild-to-severe COPD.
NETT
The NETT is a randomized multicenter treatment trial for
the investigation of outcomes in a group of individuals with
COPD randomized to conventional medical therapy versus
LVRS for the treatment of severe emphysema (NETTResearch
Group 1999). All participants had an FEV1 of 45% pre-
dicted, evidence of hyperinﬂation on pulmonary-function tests,
and emphysema on high-resolution CT scanning of the thorax
at study enrollment (NETT Research Group 1999). Of those
who were enrolled in the NETT Genetics Ancillary Study and
had blood samples available for genotyping, 304 white indi-
viduals were included as COPD cases in the present analysis.
NAS
The NAS is a longitudinal study of aging performed by the
Veterans Administration (Bell et al. 1966). At the time of study
entry, the cohort consisted of 2,280 healthy community-dwell-
ing men from the Boston area who were aged 21–80 years
old between 1961 and 1969. Since 1984, participants have
completed questionnaires regarding respiratory symptoms and
smoking history, and spirometric evaluation has been per-
formed. We selected 441 white control individuals with blood
samples available for genotyping; these individuals had no evi-
dence of airﬂow obstruction ( predicted and FEV1/FEV 1 80%1
predicted at last visit) and at least a 10–pack-yearFVC 1 90%
smoking history (Celedo´n et al. 2004).
Genotyping
Initially, seven SERPINE2 SNPs were genotyped in the Bos-
ton Early-Onset COPD Study pedigrees, NETT cases, andNAS
controls, with use of Taqman 5′ exonuclease assays, with prim-
ers obtained from Applied Biosystems (ABI). Major- and mi-
nor-allele probes were labeled with different colored ﬂuoro-
phores, and probe ﬂuorescence signal detection was performed
using the ABI Prism 7900 Sequence Detector System.
Subsequently, DNA sequencing was performed on all SER-
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Figure 4 Simulated P values for sliding-window haplotype analysis of SNPs in the NETT cases and NAS controls. Graphs of the 6-,
4-, and 2-SNP sliding window–simulated P values (Y-axis) against the midpoint SNP of each sliding window (X-axis), demonstrate the most
signiﬁcant global simulated P value for 2-SNP sliding-window haplotypes in the regions including SNPs rs7579646-rs840088 ( ),Pp .02
rs840088-rs7562213 ( ), rs7562213-rs920251 ( ), rs920251-rs1371029 ( ), rs7581619-rs3795877 ( ), rs3795877-Pp .01 Pp .01 Pp .02 Pp .02
rs1866153 ( ), rs1866153-rs6747096 ( ), rs6747096-rs3795879 ( ), rs3795879-ss49785624 ( ), ss49785624-Pp .04 Pp .004 Pp .02 Pp .02
rs6715768 ( ), and rs6715768-rs6738983 ( ).Pp .02 Pp .02
PINE2 exons and exon-intron boundaries. Sequencing efforts
in 34 COPD-affected probands from the Boston Early-Onset
COPD Study and 12 control individuals identiﬁed 17 poly-
morphisms; 4 of these polymorphisms (NCBI dbSNP Build 126
ss numbers 49785623, 49785624, 49785625, and 49785626)
had not been previously reported in public databases. For the
second round of genotyping, 41 additional SNPs (17 identiﬁed
during sequencing and 24 more from public databases) were
genotyped in both the Boston Early-Onset COPD Study fam-
ilies and NETT-NAS case-control populations, with use of the
SEQUENOM platform, for a total of 48 SNPs in both cohorts
(with 7 from the ﬁrst round and 41 from the second round of
genotyping).
Statistical Methods for Genetic Association Analysis
Pedigree-Based Association Test (PBAT).—For the fam-
ily-based single-SNP association analyses and the family-based
haplotype analyses of SERPINE2 in the Boston Early-Onset
COPD Study, we used PBAT (Lange et al. 2004) (C.L. Web
site). We had no biological data supporting a dominant or
recessive model, so we used the additive model to minimize
multiple statistical testing. The association analysis was ad-
justed for age, sex, height, smoking history (yes/no), and pack-
years of cigarette smoking and included a SNP–by–pack-years
(gene-by-environment) interaction term. Because SERPINE2
is located in a genomic region linked to COPD-related phe-
notypes, the null hypothesis of our PBAT analyses was no
association in the presence of linkage. In this setting, PBAT
adjusts for linkage by using the empirical variance in the fam-
ily-based association test (FBAT) statistic. P values .05 are
reported. For the models including the interaction term, a com-
posite P value that includes the association for the main SNP
effect and the gene-by-smoking interaction is reported. In
general, optimal model ﬁtting is possible in FBAT, by use of
the conditional-power approach as described by Lange and
Laird (2002). However, model selection that is based on con-
ditional power calculation is computationally feasible only
in the setting of small pedigrees, and this approach was not
feasible for the extended pedigrees of the Boston Early-Onset
COPD Study.
Conditional linkage models were analyzed, including the
SNP data and a SNP-by-smoking interaction term by use of a
variance component approach, as implemented in the Sequen-
tial Oligogenic Linkage Analysis Routines (SOLAR), version
1.7.4 (Almasy and Blangero 1998). Overall and smokers-only
linkage models were generated using a panel of 377 STRmark-
ers with relevant covariates (including age, sex, height, pack-
years of smoking, and SERPINE2 SNP of interest), as described
elsewhere (DeMeo et al. 2004).
Case-Control Replication Analysis.—Association be-
tween SERPINE2 SNPs and severe COPD among NETT cases
and NAS controls was investigated with the SAS Genetics pro-
gram (SAS Institute). Hardy-Weinberg equilibrium was eval-
uated among the controls for each SNP by use of the goodness-
of-ﬁt test, as implemented through SAS Genetics. Association
between each of the individual SNPs and COPD was inves-
tigated using contingency tables and by a trend test to2# 2
investigate allelic additive effects. To investigate allelic additive
effects with the Cochran-Armitage trend test and to investigate
dominance effects with the genotype case-control test, 2# 3
contingency tables were used. Since the control populationwas
all male, a males-only analysis was performed in addition to
an analysis that included all of the NETT case participants.
Haplotype frequencies were estimated, and the association
between haplotypes with a frequency 15% and COPD was
tested using global and haplotype-speciﬁc statistics with the
haplo.stats program (Schaid et al. 2002). Sliding windows of
6, 4, and 2 adjacent SNPs were used to test for association
across the SERPINE2 gene and to localize the region of most-
signiﬁcant association (Clayton and Jones 1999; Schaid et al.
2002). Simulated P values were also generated for 6-, 4-, and
2-SNP sliding windows by use of 1,000 replicates; the negative
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log of the P value was graphed against the midpoint SNP of
the sliding window to demonstrate the region of most-signif-
icant association.
Results
Mouse Expression-Array Experiments
In a microarray data set describing normal mouse lung
development generated using theAffymetrixMu11Kplat-
form (Mariani et al. 2002), 34 probe sets in the murine
data set that matched 24 independent mouse ortho-
logues for human genes were present within the region
of human chromosome 2q linkage. Expression data from
the 25 Reference Sequence–veriﬁed probe sets, repre-
senting 23 genes, are presented in ﬁgure 1. The majority
of the genes were expressed in the lung at a signal in-
tensity !4,000. Three genes were expressed at a signal
intensity 115,000 during at least one time point, in-
cluding RPL37A (a ribosomal protein), ITM2C (an in-
tegral membrane protein highly expressed in the brain),
and SERPINE2. SERPINE2 was most highly expressed
during murine alveogenesis (postnatal days 4–10) and
had the greatest expression change (4.5-fold) across the
developmental time series. This fold change was sig-
niﬁcant with use of the variable fold-change threshold
method, suggesting that this gene is regulated during
normal lung development.
Human Microarray Results
A human lung microarray data set (Spira et al. 2004)
from individuals with severe COPD and control sub-
jects was evaluated for disease-associated changes in
SERPINE2, ITM3C, and RPL37A expression (in this
region, the three most highly expressed genes during
murine lung development), by use of pulmonary-func-
tion measurements as continuous variables. SERPINE2
was positively correlated with higher TLC (Spearman
correla ; , Pearsontionp 0.46 Pp .008 correlationp
, ); this suggested a signiﬁcant correlation0.42 Pp .020
with lung hyperinﬂation. Additionally, SERPINE2 ex-
pression was inversely correlated with postbroncho-
dilator FEV1 (Spearman correlatio ;np 0.43 Pp
; Pearson correlatio ; ) and was.020 np 0.38 Pp .043
inversely correlated with DLCO (Spearman correla-
tio ; ; Pearson correlatio ;np 0.41 Pp .025 np 0.41
). Higher TLC, reduced postbronchodilatorPp .023
FEV1, and reduced DLCO are all clinical features ob-
served in patients with COPD. ITM2C and RPL37A
each had a single Reference Sequence–veriﬁed probe set;
neither showed signiﬁcant correlation to any of the pul-
monary-function measurements. Examination of these
same data with use of SAM further suggested that SER-
PINE2 expression was higher in individuals with severe
emphysema than in controls (fold change of 1.25, with
a false-discovery rate of 6.2%). This modest fold change
was veriﬁed using quantitative RT-PCR. Because of the
expression pattern of SERPINE2 across normal lung de-
velopment and the consistent correlations with COPD-
related phenotypes, we selected SERPINE2 for further
investigation.
Immunohistochemistry
We performed immunohistochemistry for SERPINE2
in postnatal mouse lungs and demonstrated prominent
immunolocalization of SERPINE2 in a cell-associated
pattern within conducting airway epithelial cells and in
an extracellular matrix-associated pattern in the vascular
adventitia (ﬁg. 2). Immunohistochemistry of adult hu-
man lungs demonstrated an analogous staining pattern
(ﬁg. 3).
PBAT
We next investigated the genetic association of a panel
of 48 SERPINE2 SNPs with COPD phenotypes (table
1). Multivariate models were evaluated in 127 pedigrees
(949 individuals) in the Boston Early-Onset COPD Study.
In additive models that included an interaction term to
capture SNP-by-smoking (gene-by-environment) effects,
18 SNPs in SERPINE2 demonstrated signiﬁcant associa-
tion with quantitative and/or qualitative spirometric phe-
notypes (tables 2 and 3).
Case-Control Association Testing
We attempted to replicate the family-based associa-
tions for SERPINE2 in a case-control analysis using 304
NETT individuals with severe smoking-related COPD
and 441 NAS controls, all smokers, with normal spi-
rometry (Celedo´n et al. 2004). As reported elsewhere,
there was no signiﬁcant evidence of population strati-
ﬁcation in these cases and controls (Celedo´n et al. 2004).
All SERPINE2 SNPs were in Hardy-Weinberg equilib-
rium in the controls. In the case-control analysis (ta-
ble 4), eight SNPs (rs1438831, rs7579646, rs840088,
rs7562213, rs920251, rs3795877, rs6747096, and
rs3795879) demonstrated signiﬁcant association (P 
), including ﬁve SNPs that were signiﬁcant in the.05
family-based analysis. In a males-only analysis, the asso-
ciation remained robust.
Haplotype Analysis
Using a sliding-window approach, we analyzed adja-
cent 6-, 4-, and 2-SNP haplotypes and observed global
signiﬁcance for the 6-, 4-, and 2-SNP haplotypes (ﬁg. 4);
this signiﬁcance was conﬁrmed with empirical P values
determined through 1,000 simulations. We used these
results to narrow our individual haplotype analyses to
these regions. With focus on the most-signiﬁcant 2-
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Table 4
Replication of Signiﬁcant Associations of SERPINE2 with COPD in the NETT Cases and NAS Controls
SNP AND SAMPLE
ALLELE AND
FREQUENCY
GENOTYPE
AND
FREQUENCY
P FOR
Allele Test Genotype Test
Males-Only
Genotype Test
rs1438831 (5′ genomic/promoter): C T CC/CT/TT .098 .089 .044
Cases .70 .30 .48/.41/.09
Controls .65 .35 .41/.49/.10
rs7579646 (intron 1): A G AA/AG/GG .043 .088 .016
Cases .17 .83 .03/.24/.73
Controls .21 .79 .04/.35/.61
rs840088 (intron 1): C T CC/CT/TT .007 .009 .008
Cases .70 .30 .51/.37/.11
Controls .63 .37 .38/.50/.13
rs7562213 (intron 1): A G AA/AG/GG .020 .018 .008
Cases .30 .70 .12/.36/.52
Controls .36 .64 .11/.50/.39
rs920251 (intron 1): A G AA/AG/GG .015 .011 .007
Cases .30 .69 .11/.39/.50
Controls .36 .64 .12/.49/.39
rs3795877 (intron 2): A G AA/AG/GG .019 .053 .005
Cases .82 .18 .72/.25/.04
Controls .77 .23 .58/.37/.05
rs6747096 (exon 3): A G AA/AG/GG .002 .005 .0006
Cases .83 .17 .73/.24/.04
Controls .76 .24 .57/.38/.05
rs3795879 (exon 3/intron 3 boundary): C T CC/CT/TT .009 .014 .0007
Cases .81 .19 .71/.24/.04
Controls .75 .25 .55/.40/.05
NOTE.—Only SNPs with signiﬁcant results ( ) in any test are shown. Signiﬁcant results are shown in bold italics.P  .05
SNP haplotype-speciﬁc associations, signiﬁcance levels
for haplotype-speciﬁc P values for FEV1/FVC in the Bos-
ton Early-Onset COPD pedigrees were similar to asso-
ciated haplotypes in the NETT-NAS case-control analy-
sis (for 2-SNP haplotype rs1438831-rs7579646, alleles
TA, family , case-control ; for 2-SNPPp .003 Pp .02
haplotype rs1866153-rs6747096, alleles CG, family
, case-control ; for SNP haplotypePp .01 Pp .001
rs6747096-rs3795879, alleles GT, family , case-Pp .047
control ).Pp .006
Conditional Linkage Models
Linkage models analyzed in SOLAR, including as co-
variates those SNPs signiﬁcant in the single-SNP and
haplotype analyses, revealed attenuation of LOD scores
for linkage to postbronchodilator FEV1/FVC on chromo-
some 2q. Speciﬁcally, inclusion of SNP rs7579646 in the
overall linkage model resulted in attenuation of the LOD
score from 4.41 (222 cM) to 2.16 (220 cM); linkage
analysis of the smokers-only model resulted in further
attenuation of the LOD score to 1.70. In this region of
the gene, attenuation of the LOD score was also ob-
served for SNPs rs840088 (LOD attenuation to 2.25
in smokers-only model) and rs7562213 (LOD attenua-
tion to 2.07 smokers-only model). Farther downstream,
LOD attenuation was observed with the inclusion of
rs3795877 (LOD attenuation to 2.22 in smokers-only
model), rs6747096 (LOD attenuation to 3.82 in smok-
ers-only model), and rs3795879 (LOD attenuation to
2.75 in smokers-only model).
Discussion
Collaborative approaches are crucial for identifying can-
didate genes and uncovering potential new pathways of
complex-disease pathogenesis. The phenotypic expression
of COPD is likely under the inﬂuence of multiple genes,
cigarette smoking (the major environmental risk factor
for COPD), and gene-by-smoking interactions. In our
study, expression-array analyses were utilized for can-
262 The American Journal of Human Genetics Volume 78 February 2006 www.ajhg.org
didate-gene prioritization in a broad linkage region on
chromosome 2q; the intersection of genomic expres-
sion-array and linkage analyses led to the identiﬁcation
of SERPINE2 as a potential COPD susceptibility gene.
Given our current state of understanding of COPDpatho-
physiology, SERPINE2 is not an obvious COPD candi-
date gene.
The SERPINE2 gene (GenBank reference sequence
NM_006216) consists of nine exons, encoding a 44-kDa
cellular and extracellular matrix-associated serine pro-
tease inhibitor, mainly involved in coagulation and ﬁbri-
nolysis (Baker et al. 1980, 1982). The major known role
of SERPINE2 is as an inhibitor of thrombin, urokinase,
and plasmin (Baker et al. 1980; Scott et al. 1985). Al-
though SERPINE2 has been extensively investigated in
the brain and has been observed to hinder neuron ap-
optosis and injury-mediated cell death (Houenou et al.
1995; Rossignol et al. 2004), there have been no studies
investigating SERPINE2 in the human lung. SERPINE2
expression has been observed in the embryonic mouse
lung within the conducting-airway epithelium (Mansuy
et al. 1993); our observation of expression in postem-
bryonic mouse and human lungs supported further in-
vestigation of the role of SERPINE2 in lung disease.
The strengths of our current approach include the iden-
tiﬁcation of a plausible positional candidate gene for
COPD by expression analysis and immunohistochemistry
and by demonstration of signiﬁcant association of mul-
tiple SNPs in SERPINE2 in extended pedigrees, replica-
tion in an independent case-control study, and signiﬁ-
cance at both the single-SNP and haplotype levels. Al-
though multiple statistical testing may yield false-posi-
tive associations, independent replication suggests that
these are likely valid associations. LOD score attenua-
tion in overall and smoking-stratiﬁed linkage models is
further support of SERPINE2 as a COPD candidate gene.
The data from the microarray experiments guided fur-
ther investigation, hypothesis generation, and candidate-
gene selection. One weakness of this approach is that
expression changes in the lung are subject to variations
in sampling that are unavoidable in a complex and het-
erogeneous tissue, and gene expression changes detected
in end-stage tissue may not be restricted to those involved
in COPD mechanisms (and may be secondary or com-
pensatory responses). Although the human control sam-
ples may not have had completely normal lungs, the
combination of the microarray data and immunohisto-
chemistry supported our further investigation of SER-
PINE2. Weaknesses of our association studies include
the potential heterogeneity of disease phenotypes be-
tween our different human populations. However, lim-
iting the potential heterogeneity is the fact that both the
Boston Early-Onset COPD probands and theNETT cases
represent individuals with very severe COPD. The rep-
licated association of multiple SNPs in SERPINE2 sug-
gests that the next phase of investigation of SERPINE2
in the lung should include association analysis of a com-
prehensive set of SERPINE2 SNPs and assessment of
potential functional variants, as well as the consideration
of ﬁbrinolytic pathways in the pathogenesis of COPD.
We have not observed complete attenuation of our LOD
scores to zero in conditional linkage models; this sug-
gests that other variants in the SERPINE2 gene, or more
likely variants in another COPD-susceptibility gene in
the region, contribute to the linkage signal in this region
on chromosome 2q.
Amechanism through which SERPINE2may contrib-
ute to the development of COPD has yet to be identiﬁed.
To date, the expression of SERPINE2 has been most
extensively studied in the brain and reproductive system;
as such, it is a surprising candidate for association with
COPD. However, SERPINE2 does belong to the serpin
family of proteins, as does alpha 1-antitrypsin, deﬁciency
of which is the only known genetic cause of COPD. Our
results suggest that overexpression of SERPINE2, rather
than deﬁciency, is associated with COPD. Nonetheless,
the aggregate results of family-based and case-control
single-SNP and haplotype association analyses, as well
as the conditional linkage results demonstrating LOD
score attenuation, suggest the strongest signiﬁcance of
variants in or in linkage disequilibrium with intron 1
and exon 3 of the SERPINE2 gene.
Alterations in coagulation and ﬁbrinolytic pathways
have been associated with acute and chronic lung injury
and airway hyperresponsiveness, but extensive investi-
gation in the setting of COPD has yet to be performed
(Chambers 2003; Idell 2003; Wagers et al. 2004). Al-
though there has been occasional speculation in the past
regarding the role of vascular thrombosis and hyper-
coaguability in the development of emphysema, this has
not been widely investigated (Brantigan et al. 1966; Ales-
sandri et al. 1994; Ashitani et al. 2002). SERPINE2 has
been demonstrated to be an inhibitor of trypsinlike ser-
ine proteases (such as thrombin, trypsin, plasmin, and
urokinase); SERPINE2 has not been demonstrated to
inhibit neutrophil elastase or chymotrypsinlike proteases
(Scott et al. 1985). In addition to proteolytic stress, im-
balance in oxidant-antioxidant pathways are potentially
important in the development of COPD. To date, we are
not aware of any studies of oxidative regulation of SER-
PINE2 activity.
There exists a complex mechanism of cross talk be-
tween serine proteases (and their inhibitors) and metal-
loproteinases (and their inhibitors), particularly within
the lung and in relation to the pathogenesis of emphy-
sema, a major component of COPD. For instance, the
serine protease neutrophil elastase is capable of degrad-
ing metalloproteinase inhibitors (TIMPs), whereas the
metalloproteinase macrophage elastase (MMP-12) is ca-
pable of degrading the neutrophil elastase inhibitor al-
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pha 1-antitrypsin (Shapiro et al. 2003). Plasmin, one of
the potential substrates for SERPINE2, is also capable
of contributing to metalloproteinase activation. Poly-
morphic variants in the SERPINE2 gene could contrib-
ute to the development of COPD through alterations in
matrix metalloproteinase pathways. The physiological
substrate for SERPINE2 within the lung and the impact
of alterations in expression on the complex coordination
of proteolytic activities and imbalances in the exposure
to cigarette smoke remain to be deﬁned.
In summary, through the intersection of murine and
human microarray analyses with linkage information on
chromosome 2q, we have demonstrated replicated asso-
ciation of SERPINE2 variants with COPD. SERPINE2
may have a role in deﬁning susceptibility phenotypes of
COPD by inﬂuencing inﬂammatory responses to environ-
mental exposures such as cigarette smoke through gene-
by-smoking interactions. SERPINE2 has been demon-
strated to inhibit extracellular matrix destruction (Berg-
man et al. 1986), which suggests that polymorphisms
in the SERPINE2 gene may inﬂuence alterations in re-
pair of smoking-induced lung damage. More research is
needed to identify critical variants in the gene as well as
to deﬁne a functional role for SERPINE2 in COPD.
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